Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 921.9% in April

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 191,100 shares, an increase of 921.9% from the March 31st total of 18,700 shares. Currently, 7.6% of the shares of the company are sold short. Based on an average trading volume of 210,400 shares, the short-interest ratio is presently 0.9 days.

Vivos Therapeutics Stock Performance

Shares of NASDAQ VVOS opened at $2.59 on Friday. Vivos Therapeutics has a 12 month low of $2.37 and a 12 month high of $48.79. The company has a 50 day simple moving average of $4.05 and a two-hundred day simple moving average of $6.74.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($3.05) EPS for the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative return on equity of 665.17%. The business had revenue of $3.25 million for the quarter.

Institutional Trading of Vivos Therapeutics

An institutional investor recently bought a new position in Vivos Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned approximately 4.29% of Vivos Therapeutics at the end of the most recent reporting period. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.